More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says
More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved for Crohn’s disease last year — dramatically impacted the switching patterns, according to the findings. More than 1,000 medical records of IBD patients who switched biologics for either Crohn’s disease or ulcerative colitis were included in the analysis. One hundred eighty-seven gastroenterologists took part in the review. A biologic is a therapy derived from a biological source rather than chemicals. The report showed that Stelara, which blocks the inflammatory molecules IL-12 and IL-23, is now the most preferred second-line drug that does not target tumor necrosis factor (TNF). Takeda’s Entyvio (vedolizumab) was the second-line leader last year. Tumor necrosis factor is a cell signaling protein implicated in a number of diseases, including IBD. TNF blockers remain the most popular treatment choice for bowel disease, the report indicated. Many d
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *